Arrowhead (ARWR) announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational RNA interference therapeutic being developed as a potential treatment for tauopathies including Alzheimer’s disease, a progressive neurodegenerative disease characterized by cognitive and functional decline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Sarepta price target raised to $15 from $12 at Leerink
- Cautious Optimism: Hold Rating for Arrowhead Pharmaceuticals Amid Novartis Collaboration and Balance Sheet Concerns
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Arrowhead (ARWR) Stock Soars over $200M Deal with Swiss Pharma Giant Novartis
- Hold Rating on Arrowhead Pharmaceuticals Amid Strategic Partnership and Market Competition